Craig W Canfield, MD
Urology · San Luis Obispo
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
- Since medical school
- 33 years
- Graduated 1993
Offices
1 location · Urology Associates of the Central Coast · 13 clinicians in this group
Hospitals listed: Adventist Health Sierra Vista · Adventist Health Twin Cities · French Hospital Medical Center · Marian Regional Medical Center. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Canfield’s office at (805) 541-1111 to ask if they take your plan before you enroll.
California Medical Board record
Licence G64478 · Current
Licensed to practise in California · since 1988 · expires 2028-06-30 · University of Texas Medical School at San Antonio.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Urology - Urology
Hospitals they work in
4 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Adventist Health Sierra VistaSan Luis Obispo, CAAcute Care Hospital · Proprietary · Has an emergency department · Birthing-friendlyPart of Tenet Healthcare, which runs 77 hospitals in 12 statesPatients rate it 2 of 5 · 57% would definitely recommend itOverall rating: 3 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.273, Oct 2024 – Sep 2025
- Adventist Health Twin CitiesTempleton, CAAcute Care Hospital · Proprietary · Has an emergency department · Birthing-friendlyPart of Tenet Healthcare, which runs 77 hospitals in 12 statesPatients rate it 3 of 5 · 60% would definitely recommend itOverall rating: 2 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.41, Oct 2024 – Sep 2025
- French Hospital Medical CenterSan Luis Obispo, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of CommonSpirit Health, which runs 145 hospitals in 19 statesPatients rate it 3 of 5 · 78% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.23, Oct 2024 – Sep 2025
- Marian Regional Medical CenterSanta Maria, CAAcute Care Hospital · Voluntary non-profit - Church · Has an emergency department · Birthing-friendlyPart of CommonSpirit Health, which runs 145 hospitals in 19 statesPatients rate it 3 of 5 · 68% would definitely recommend itOverall rating: 3 of 5 starsBetter than the national rate — CMS Medicare PSI 90: Patient safety and adverse events composite: 0.67 (0.37 to 0.96), Jul 2022 – Jun 2024Better than the national rate — Clostridium Difficile (C.Diff): 0.081, Oct 2024 – Sep 2025
See every measure and the patient survey for Adventist Health Sierra Vista
Behind the star rating — Deaths: 0 better, 6 the same, 0 worse of 6 measures. Safety: 1 better, 5 the same, 0 worse of 6 measures. Readmissions: 1 better, 5 the same, 1 worse of 7 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.273 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.19 (0.16 to 2.21) · 577 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.96 (0.54 to 1.38) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 218.26 (161.19 to 275.34) · 33 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 7.6 · 31 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 11.6 · 72 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 19.1 · 175 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 11.5 · 76 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 4 · 874 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.19 (0 to 0.41) · 2,390 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.32 (0.12 to 0.53) · 2,282 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.97 (0.7 to 5.24) · 665 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.66 (0 to 3.38) · 94 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.51 (0.92 to 4.09) · 654 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.57 (0 to 18.3) · 90 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.12 (0.83 to 9.41) · 80 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.99 (0.5 to 3.48) · 231 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.62 (0 to 1.53) · 2,070 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 5.7 · 35 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.729 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.63 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.924 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.1 · 73 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 67.8 · 79 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 7 · 168 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.9 · 163 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.6 · 33 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.7 · 41 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.3 (9.2 to 16.6) · 652 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.3 (0.9 to 1.7) · 210 cases | No different | Jan 2024 – Dec 2024 |
What patients said (559 patients answered, 19% of those asked)
| Cleanliness | 2 |
| Nurse communication | 2 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 2 |
| Quietness | 1 |
| Recommend hospital | 2 |
| Room was "always" clean | 60% |
| Nurses "always" communicated well | 72% |
| Doctors "always" communicated well | 73% |
| Staff "always" explained | 57% |
| Yes, staff "did" give patients this information | 87% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 66% |
| Doctors "always" listened carefully | 71% |
| Doctors "always" treated them with courtesy and respect | 81% |
| Patients who gave a rating of "9" or "10" (high) | 53% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 69% |
| Nurses "always" listened carefully | 67% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 34% |
| "YES", patients would definitely recommend the hospital | 57% |
| Staff "always" explained possible side effects | 43% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
See every measure and the patient survey for Adventist Health Twin Cities
Behind the star rating — Deaths: 0 better, 5 the same, 0 worse of 5 measures. Safety: 1 better, 4 the same, 0 worse of 5 measures. Readmissions: 0 better, 5 the same, 2 worse of 7 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.41 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1 (0 to 2.06) · 359 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.94 (0.51 to 1.38) | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 7.2 · 66 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 12.7 · 198 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 16.6 · 335 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 11.9 · 113 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.7 · 1,156 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.26 (0.03 to 0.48) · 2,873 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.29 (0.08 to 0.5) · 2,701 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.28 (1.85 to 6.72) · 375 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.66 (0 to 3.39) · 38 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.53 (0.84 to 4.22) · 371 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.14 (0 to 19.18) · 39 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.21 (0.88 to 9.54) · 31 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.71 (0.2 to 3.22) · 97 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.32 (0 to 1.28) · 2,369 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 5.4 · 41 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 1.704 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21.9 · 257 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 40.3 · 216 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 6.5 · 313 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.3 · 300 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.5 · 39 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 18.9 · 69 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.9 (10.4 to 18.7) · 246 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.8 to 1.4) · 220 cases | No different | Jan 2024 – Dec 2024 |
What patients said (555 patients answered, 20% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 2 |
| Quietness | 1 |
| Recommend hospital | 2 |
| Room was "always" clean | 67% |
| Nurses "always" communicated well | 76% |
| Doctors "always" communicated well | 75% |
| Staff "always" explained | 60% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 73% |
| Doctors "always" treated them with courtesy and respect | 82% |
| Patients who gave a rating of "9" or "10" (high) | 63% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 74% |
| Nurses "always" listened carefully | 72% |
| Nurses "always" treated them with courtesy and respect | 81% |
| "Always" quiet at night | 35% |
| "YES", patients would definitely recommend the hospital | 60% |
| Staff "always" explained possible side effects | 45% |
| Yes, staff "did" give patients information about possible symptoms | 87% |
See every measure and the patient survey for French Hospital Medical Center
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 1 better, 5 the same, 0 worse of 6 measures. Readmissions: 2 better, 7 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.23 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.89 (0 to 1.89) · 660 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.71 (0.39 to 1.04) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 154.33 (99.56 to 209.1) · 63 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.5 · 78 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.9 · 56 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.3 · 273 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 13.7 · 355 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.8 · 275 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.5 · 69 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.7 · 1,569 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.2 (0 to 0.4) · 4,085 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.07 to 0.47) · 4,358 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.69 (0.53 to 4.85) · 1,221 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.97 (0.47 to 3.48) · 567 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.54 (1.03 to 4.05) · 1,101 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 6.3 (0.36 to 12.23) · 585 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 3.66 (0.03 to 7.29) · 576 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.98 (0.5 to 3.47) · 185 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.2 (0 to 0.96) · 3,231 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.2 · 53 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 2.935 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.6 · 252 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.5 · 330 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -2.9 · 296 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -8.5 · 382 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 2 · 272 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.9 · 248 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.1 (3.2 to 8) · 25 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 9.7 (6.5 to 14.1) · 25 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.5 · 40 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10 · 77 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 11.7 (8.9 to 15.1) · 837 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.2) · 706 cases | No different | Jan 2024 – Dec 2024 |
What patients said (706 patients answered, 28% of those asked)
| Cleanliness | 3 |
| Nurse communication | 4 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 1 |
| Recommend hospital | 5 |
| Room was "always" clean | 68% |
| Nurses "always" communicated well | 80% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 62% |
| Yes, staff "did" give patients this information | 90% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 72% |
| Staff "always" explained new medications | 77% |
| Nurses "always" explained things so they could understand | 75% |
| Nurses "always" listened carefully | 77% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 33% |
| "YES", patients would definitely recommend the hospital | 78% |
| Staff "always" explained possible side effects | 48% |
| Yes, staff "did" give patients information about possible symptoms | 91% |
See every measure and the patient survey for Marian Regional Medical Center
Behind the star rating — Deaths: 0 better, 7 the same, 1 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 1 better, 8 the same, 2 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.67 (0.37 to 0.96) | Better | Jul 2022 – Jun 2024 |
| Clostridium Difficile (C.Diff)Infections | 0.081 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.99 (0.06 to 1.93) · 1,191 cases | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 189.73 (139.29 to 240.17) · 66 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 3.7 · 103 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.8 · 161 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 15.9 · 247 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 10.7 · 478 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.4 · 470 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.5 · 237 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.5 · 3,050 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.14 (0 to 0.34) · 8,823 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.24 (0.05 to 0.42) · 8,672 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.87 (0.97 to 4.76) · 2,024 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2.12 (0.57 to 3.67) · 782 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.29 (0.85 to 3.72) · 1,934 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 3.63 (0 to 9.97) · 787 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.01 (1.37 to 8.65) · 748 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.88 (0.43 to 3.32) · 373 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.13 (0 to 0.73) · 6,968 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.1 · 179 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.245 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.85 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.952 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.687 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.5 · 198 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21.6 · 469 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 18.8 · 232 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -9.8 · 541 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -8.6 · 473 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.8 · 434 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.6 (5 to 8.4) · 519 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.9 (8.8 to 13.4) · 519 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.2 · 152 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11.3 · 83 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 18.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.4 (9.2 to 17) · 124 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.1 (0.9 to 1.4) · 638 cases | No different | Jan 2024 – Dec 2024 |
What patients said (666 patients answered, 17% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 76% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 77% |
| Staff "always" explained | 64% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 72% |
| Doctors "always" listened carefully | 73% |
| Doctors "always" treated them with courtesy and respect | 85% |
| Patients who gave a rating of "9" or "10" (high) | 67% |
| Staff "always" explained new medications | 79% |
| Nurses "always" explained things so they could understand | 76% |
| Nurses "always" listened carefully | 74% |
| Nurses "always" treated them with courtesy and respect | 87% |
| "Always" quiet at night | 47% |
| "YES", patients would definitely recommend the hospital | 68% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 89% |
Original Medicare doctor bills
$949,606
Medicare paid this office $949,606 for 2,268 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 1,531 | $227,519 | $95 |
| Injection, denosumab, 1 mg | 31 | $176,374 | None |
| Short return visit (20+ min) | 738 | $60,872 | $67 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 58 | $51,923 | None |
| Injection, testosterone undecanoate, 1 mg | 19 | $39,735 | None |
See all 42 services
| Return visit (30+ min) | 1,531 | $227,519 | $95 |
| Injection, denosumab, 1 mg | 31 | $176,374 | None |
| Short return visit (20+ min) | 738 | $60,872 | $67 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 58 | $51,923 | None |
| Injection, testosterone undecanoate, 1 mg | 19 | $39,735 | None |
| Diagnostic exam of bladder and urethra using an endoscope | 166 | $34,760 | $189 |
| Unclassified drugs | 13 | $18,521 | None |
| New patient visit (45+ min) | 154 | $18,163 | $118 |
| Shock wave crushing of kidney stones | 32 | $17,251 | $539 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 1,064 | $16,472 | $12 |
| Insertion of lower leg neurostimulator electrode | 33 | $12,170 | $97 |
| Botox | 11 | $10,888 | None |
| Removal of prostate gland using an electrocautery knife through urethra with control of bleeding using an endoscope | 18 | $10,311 | $573 |
| Biopsy of prostate gland | 45 | $8,251 | $183 |
| Exam with injections of chemical for destruction of bladder using an endoscope | 11 | $5,892 | $327 |
| Insertion of device into abdomen with pressure and urine flow rate study | 34 | $5,736 | $164 |
| Bcg live intravesical instillation, 1 mg | 18 | $5,461 | None |
| Complex measurement of pressure of urine flow in bladder with voiding pressure studies | 18 | $5,234 | $291 |
| Complex measurement of pressure of urine flow in bladder with urethra pressure and voiding pressure studies | 16 | $4,931 | $290 |
| Destruction and/or removal of growth of bladder and urethra using an endoscope, 2.0-5.0 cm | 18 | $4,286 | $214 |
| New patient visit (30+ min) | 53 | $3,941 | $74 |
| Automated urinalysis test | 1,214 | $3,826 | $2 |
| Instillation of anti-cancer drug into bladder | 19 | $3,661 | $75 |
| Ultrasound measurement of bladder capacity after voiding | 319 | $3,547 | $9 |
| Complicated insertion of bladder tube | 20 | $3,488 | $120 |
| Destruction and/or removal of large growth of bladder using an endoscope | 11 | $3,365 | $306 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 58 | $3,175 | $31 |
| Ultrasonic guidance for needle placement | 54 | $2,985 | $47 |
| Placement of hormone pellet under skin | 13 | $2,896 | $78 |
| Short return visit | 53 | $2,874 | $41 |
| Placement of device in prostate for radiation therapy | 19 | $2,150 | $113 |
| Injection of drug or substance under skin or into muscle | 91 | $1,979 | $12 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 16 | $1,652 | $103 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 17 | $1,502 | $88 |
| Tissue marker, implantable, any type, each | 19 | $1,469 | $26 |
| Insertion of stent in ureter using an endoscope | 16 | $1,468 | $86 |
| Pelvic exam | 45 | $1,252 | $19 |
| Non-needle measurement and recording of electrical activity of muscles at bladder and bowel openings | 34 | $937 | $27 |
| Insertion of temporary bladder tube | 12 | $447 | $37 |
| Imaging of urinary tract following injection of a contrast agent | 15 | $330 | $19 |
| Electronic assessment of bladder emptying | 34 | $205 | $6 |
| Injection, ceftriaxone sodium, per 250 mg | 39 | $17 | None |
Procedures Medicare counted
| Prostate resection | 32 | More than 91% of doctors who do this |
Procedures year by year
| Procedure | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Ultrasound measurement of bladder capacity after voiding | 279 | 420 | 359 | 222 | 541 | 398 |
| Diagnostic exam of bladder and urethra using an endoscope | 202 | 187 | 181 | 167 | 195 | 184 |
| Insertion of lower leg neurostimulator electrode | 113 | 68 | 169 | 54 | 191 | 125 |
| Placement of hormone pellet under skin | 69 | 41 | 62 | 58 | 48 | 37 |
| Biopsy of prostate gland | 30 | 33 | 40 | 43 | 45 | 45 |
| Instillation of anti-cancer drug into bladder | – | – | 65 | 52 | 51 | 49 |
Times billed to Original Medicare each year. A blank year means fewer than 11 people had it, or none: Medicare does not publish smaller counts. Medicare Advantage patients are not included.
Who their Medicare patients are
2,268 Original Medicare patients in 2024. Average age 76 · Under 65 3% · 85 and older 14% · Women 27% · Also on Medicaid 8% · Health risk score 1.10. At or below the middle of the specialty; the typical urology clinician is at 1.36.
Conditions among them: High blood pressure 71% · Cancer 28% · Coronary heart disease 26% · Chronic kidney disease 22% · Diabetes 20% · Atrial fibrillation 20% · Depression 16% · Heart failure 11% · COPD 11% · Stroke 7% · Dementia 5%.
The office billed $2,293,057, Medicare allowed $1,255,194 and paid $949,606; for 49,520 services of 95 kinds; $417,671 of it was for drugs given in the office and $531,935 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 2,268 | 49,520 | 76 | 1.10 | $2,293,057 | $949,606 |
| 2023 | 2,278 | 66,372 | 76 | 1.06 | $2,269,130 | $919,342 |
| 2022 | 1,811 | 68,214 | 76 | 1.01 | $2,122,003 | $910,449 |
| 2021 | 2,039 | 86,215 | 75 | 1.05 | $2,377,794 | $1,027,633 |
| 2020 | 1,826 | 68,025 | 75 | 1.08 | $1,808,540 | $827,222 |
| 2019 | 1,798 | 16,779 | 75 | 1.13 | $1,512,103 | $689,413 |
| 2018 | 1,967 | 24,640 | 75 | 1.19 | $1,594,693 | $739,870 |
| 2017 | 1,884 | 23,067 | 75 | 1.23 | $1,564,817 | $782,982 |
| 2016 | 1,859 | 27,869 | 75 | 1.24 | $1,564,158 | $707,423 |
| 2015 | 1,785 | 20,435 | 75 | 1.17 | $1,359,529 | $608,094 |
| 2014 | 1,571 | 17,723 | 75 | 1.09 | $1,334,501 | $642,109 |
| 2013 | 1,865 | 15,975 | 75 | 1.21 | $1,181,903 | $817,391 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 43 services
| Return visit (30+ min) | 1,336 | $197,155 | $96 |
| Injection, denosumab, 1 mg | 26 | $130,292 | None |
| Short return visit (20+ min) | 1,116 | $97,034 | $66 |
| Injection, testosterone undecanoate, 1 mg | 28 | $63,808 | None |
| Leuprolide acetate (for depot suspension), 7.5 mg | 56 | $52,058 | None |
| Diagnostic exam of bladder and urethra using an endoscope | 172 | $37,459 | $192 |
| Unclassified drugs | 16 | $23,910 | None |
| New patient visit (45+ min) | 151 | $19,603 | $130 |
| Insertion of lower leg neurostimulator electrode | 41 | $19,371 | $101 |
| Removal of prostate gland using an electrocautery knife through urethra with control of bleeding using an endoscope | 27 | $15,751 | $583 |
| Botox | 14 | $12,747 | None |
| Shock wave crushing of kidney stones | 22 | $10,911 | $496 |
| Biopsy of prostate gland | 45 | $8,952 | $199 |
| Complex measurement of pressure of urine flow in bladder with voiding pressure studies | 26 | $8,261 | $318 |
| Insertion of device into abdomen with pressure and urine flow rate study | 49 | $8,115 | $166 |
| Complex measurement of pressure of urine flow in bladder with urethra pressure and voiding pressure studies | 24 | $7,523 | $313 |
| Exam with injections of chemical for destruction of bladder using an endoscope | 14 | $6,680 | $334 |
| New patient visit (30+ min) | 78 | $6,493 | $83 |
| Bcg live intravesical instillation, 1 mg | 22 | $5,432 | None |
| Automated urinalysis test | 1,347 | $4,948 | $2 |
| Ultrasound measurement of bladder capacity after voiding | 349 | $4,742 | $9 |
| Placement of hormone pellet under skin | 16 | $3,788 | $79 |
| Complicated insertion of bladder tube | 20 | $3,692 | $123 |
| Instillation of anti-cancer drug into bladder | 21 | $3,647 | $72 |
| Dilation of urethra using an endoscope | 12 | $3,641 | $280 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 59 | $3,403 | $29 |
| Simple change of bladder tube | 12 | $3,305 | $77 |
| Ultrasonic guidance for needle placement | 48 | $2,870 | $49 |
| Short return visit | 56 | $2,828 | $44 |
| Destruction and/or removal of growth of bladder and urethra using an endoscope, 2.0-5.0 cm | 14 | $2,539 | $159 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 17 | $2,397 | $141 |
| Injection of drug or substance under skin or into muscle | 88 | $1,926 | $12 |
| Insertion of stent in ureter using an endoscope | 16 | $1,825 | $96 |
| Placement of device in prostate for radiation therapy | 13 | $1,660 | $128 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 14 | $1,390 | $99 |
| Non-needle measurement and recording of electrical activity of muscles at bladder and bowel openings | 50 | $1,322 | $26 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 13 | $1,028 | $64 |
| Simple bladder irrigation and/or instillation | 16 | $947 | $50 |
| Simple insertion of temporary bladder tube | 12 | $897 | $53 |
| Tissue marker, implantable, any type, each | 13 | $866 | $22 |
| Imaging of urinary tract following injection of a contrast agent | 15 | $318 | $20 |
| Electronic assessment of bladder emptying | 49 | $280 | $6 |
| Injection, ceftriaxone sodium, per 250 mg | 29 | $19 | None |
2022: 35 services
| Return visit (30+ min) | 890 | $135,223 | $97 |
| Injection, denosumab, 1 mg | 25 | $124,066 | None |
| Short return visit (20+ min) | 1,077 | $102,295 | $66 |
| Injection, testosterone undecanoate, 1 mg | 20 | $62,660 | None |
| Leuprolide acetate (for depot suspension), 7.5 mg | 53 | $51,989 | None |
| Diagnostic exam of bladder and urethra using an endoscope | 146 | $32,859 | $197 |
| Unclassified drugs | 18 | $29,873 | None |
| New patient visit (45+ min) | 145 | $17,567 | $121 |
| Botox | 12 | $16,444 | None |
| Shock wave crushing of kidney stones | 29 | $14,228 | $491 |
| Removal of prostate gland using an electrocautery knife through urethra with control of bleeding using an endoscope | 23 | $13,592 | $591 |
| Exam with injections of chemical for destruction of bladder using an endoscope | 12 | $8,155 | $340 |
| Biopsy of prostate gland | 43 | $8,143 | $189 |
| Complex measurement of pressure of urine flow in bladder with urethra pressure and voiding pressure studies | 20 | $6,573 | $329 |
| Insertion of device into abdomen with pressure and urine flow rate study | 34 | $5,904 | $174 |
| New patient visit (30+ min) | 74 | $5,799 | $78 |
| Insertion of lower leg neurostimulator electrode | 20 | $4,804 | $89 |
| Bcg live intravesical instillation, 1 mg | 16 | $4,600 | None |
| Placement of hormone pellet under skin | 18 | $4,532 | $78 |
| Complex measurement of pressure of urine flow in bladder with voiding pressure studies | 14 | $4,158 | $297 |
| Automated urinalysis test | 1,033 | $3,688 | $2 |
| Instillation of anti-cancer drug into bladder | 16 | $3,655 | $70 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 55 | $3,292 | $28 |
| Destruction and/or removal of growth of bladder and urethra using an endoscope, 2.0-5.0 cm | 11 | $2,658 | $204 |
| Ultrasonic guidance for needle placement | 45 | $2,369 | $48 |
| Insertion of stent in ureter using an endoscope | 20 | $2,250 | $98 |
| Injection of drug or substance under skin or into muscle | 83 | $2,069 | $12 |
| Ultrasound measurement of bladder capacity after voiding | 180 | $1,860 | $8 |
| Short return visit | 40 | $1,697 | $42 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 14 | $1,531 | $109 |
| Non-needle measurement and recording of electrical activity of muscles at bladder and bowel openings | 35 | $945 | $27 |
| Simple bladder irrigation and/or instillation | 13 | $661 | $47 |
| Imaging of urinary tract following injection of a contrast agent | 14 | $283 | $20 |
| Electronic assessment of bladder emptying | 34 | $195 | $6 |
| Injection, ceftriaxone sodium, per 250 mg | 35 | $17 | None |
2021: 41 services
| Injection, denosumab, 1 mg | 17 | $145,385 | None |
| Short return visit (20+ min) | 1,380 | $139,548 | $68 |
| Return visit (30+ min) | 873 | $128,356 | $101 |
| Injection, testosterone undecanoate, 1 mg | 29 | $72,735 | None |
| Leuprolide acetate (for depot suspension), 7.5 mg | 52 | $59,066 | None |
| Diagnostic exam of bladder and urethra using an endoscope | 156 | $34,260 | $189 |
| Unclassified drugs | 20 | $32,460 | None |
| Shock wave crushing of kidney stones | 36 | $20,456 | $538 |
| New patient visit (45+ min) | 162 | $19,341 | $119 |
| Insertion of lower leg neurostimulator electrode | 34 | $18,908 | $112 |
| Botox | 13 | $11,592 | None |
| Removal of prostate gland using an electrocautery knife through urethra with control of bleeding using an endoscope | 18 | $10,432 | $580 |
| Complex measurement of pressure of urine flow in bladder with urethra pressure and voiding pressure studies | 27 | $9,286 | $344 |
| Injection, degarelix, 1 mg | 14 | $8,684 | None |
| Biopsy of prostate gland | 39 | $8,490 | $212 |
| Insertion of device into abdomen with pressure and urine flow rate study | 46 | $7,648 | $166 |
| Bcg live intravesical instillation, 1 mg | 16 | $6,473 | None |
| Exam with injections of chemical for destruction of bladder using an endoscope | 13 | $6,075 | $337 |
| Complex measurement of pressure of urine flow in bladder with voiding pressure studies | 19 | $6,068 | $319 |
| New patient visit (30+ min) | 76 | $5,791 | $76 |
| Instillation of anti-cancer drug into bladder | 17 | $4,994 | $77 |
| Placement of hormone pellet under skin | 20 | $4,825 | $78 |
| Automated urinalysis test | 1,234 | $4,678 | $2 |
| Dilation of urethra using an endoscope | 14 | $4,617 | $289 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 59 | $4,145 | $28 |
| Crushing of stone of ureter with insertion of stent using an endoscope | 11 | $3,756 | $313 |
| Destruction and/or removal of growth of bladder and urethra using an endoscope, 2.0-5.0 cm | 14 | $2,949 | $211 |
| Ultrasound measurement of bladder capacity after voiding | 275 | $2,907 | $8 |
| Injection of drug or substance under skin or into muscle | 104 | $2,686 | $12 |
| Simple bladder irrigation and/or instillation | 31 | $2,228 | $59 |
| Ultrasonic guidance for needle placement | 39 | $2,190 | $50 |
| Insertion of stent in ureter using an endoscope | 20 | $2,117 | $101 |
| Simple change of bladder tube | 11 | $1,980 | $79 |
| Short return visit | 38 | $1,963 | $47 |
| Insertion of temporary bladder tube | 35 | $1,443 | $36 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 12 | $1,351 | $113 |
| Non-needle measurement and recording of electrical activity of muscles at bladder and bowel openings | 46 | $1,304 | $28 |
| Imaging of urinary tract following injection of a contrast agent | 16 | $375 | $21 |
| Electronic assessment of bladder emptying | 38 | $219 | $6 |
| Injection, garamycin, gentamicin, up to 80 mg | 15 | $69 | None |
| Injection, ceftriaxone sodium, per 250 mg | 42 | $44 | None |
2020: 40 services
| Short return visit (20+ min) | 1,479 | $145,786 | $56 |
| Injection, denosumab, 1 mg | 12 | $79,697 | None |
| Leuprolide acetate (for depot suspension), 7.5 mg | 46 | $61,871 | None |
| Injection, testosterone undecanoate, 1 mg | 29 | $57,014 | None |
| Return visit (30+ min) | 422 | $49,490 | $86 |
| Diagnostic exam of bladder and urethra using an endoscope | 162 | $31,867 | $170 |
| Unclassified drugs | 26 | $20,596 | None |
| New patient visit (45+ min) | 97 | $11,812 | $122 |
| Shock wave crushing of kidney stones | 23 | $11,434 | $497 |
| New patient visit (30+ min) | 151 | $10,888 | $72 |
| Botox | 13 | $10,444 | None |
| Removal of prostate gland using an electrocautery knife through urethra with control of bleeding using an endoscope | 13 | $7,808 | $601 |
| Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | 31 | $7,407 | $31 |
| Complex measurement of pressure of urine flow in bladder with voiding pressure studies | 24 | $7,323 | $305 |
| Removal of stent in ureter through ureter with review by radiologist | 11 | $7,163 | $651 |
| Insertion of lower leg neurostimulator electrode | 14 | $7,131 | $105 |
| Biopsy of prostate gland | 31 | $6,621 | $201 |
| Insertion of device into abdomen with pressure and urine flow rate study | 41 | $5,707 | $139 |
| Exam with injections of chemical for destruction of bladder using an endoscope | 13 | $4,993 | $312 |
| Complex measurement of pressure of urine flow in bladder with urethra pressure and voiding pressure studies | 17 | $4,992 | $294 |
| Automated urinalysis test | 1,117 | $4,073 | $2 |
| Ultrasound measurement of bladder capacity after voiding | 286 | $3,412 | $8 |
| Placement of hormone pellet under skin | 26 | $3,249 | $79 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 50 | $3,011 | $27 |
| Destruction and/or removal of growth of bladder and urethra using an endoscope, 2.0-5.0 cm | 11 | $2,927 | $244 |
| Injection of drug or substance under skin or into muscle | 88 | $1,988 | $12 |
| Simple insertion of temporary bladder tube | 25 | $1,963 | $50 |
| Ultrasonic guidance for needle placement | 36 | $1,922 | $47 |
| Simple change of bladder tube | 12 | $1,804 | $75 |
| Simple bladder irrigation and/or instillation | 21 | $1,752 | $55 |
| Insertion of stent in ureter using an endoscope | 13 | $1,370 | $105 |
| Non-needle measurement and recording of electrical activity of muscles at bladder and bowel openings | 41 | $1,158 | $28 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 28 | $1,101 | $18 |
| Psa (prostate specific antigen) measurement, complexed | 57 | $1,045 | $18 |
| Insertion of temporary bladder tube | 19 | $885 | $38 |
| Electronic assessment of bladder emptying | 37 | $220 | $6 |
| Insertion of needle into vein for collection of blood sample | 58 | $171 | $3 |
| Injection, garamycin, gentamicin, up to 80 mg | 15 | $68 | None |
| Manual urinalysis test with examination using microscope, automated | 16 | $54 | $3 |
| Injection, ceftriaxone sodium, per 250 mg | 32 | $41 | None |
2019: 33 services
| Short return visit (20+ min) | 1,414 | $128,781 | $56 |
| Return visit (30+ min) | 472 | $53,387 | $81 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 42 | $53,025 | None |
| Unclassified drugs | 26 | $33,288 | None |
| Diagnostic exam of bladder and urethra using an endoscope | 179 | $30,741 | $152 |
| Destruction of prostate tissue using radiofrequency induced heated water vapor | 14 | $22,026 | $1,573 |
| New patient visit (45+ min) | 149 | $18,010 | $121 |
| Removal of prostate gland using an electrocautery knife through urethra with control of bleeding using an endoscope | 23 | $13,798 | $600 |
| Insertion of lower leg neurostimulator electrode | 30 | $11,690 | $103 |
| Shock wave crushing of kidney stones | 21 | $10,041 | $478 |
| New patient visit (30+ min) | 126 | $9,456 | $75 |
| Botox | 12 | $8,655 | None |
| Biopsy of prostate gland | 30 | $6,078 | $203 |
| Placement of hormone pellet under skin | 27 | $5,391 | $78 |
| Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | 50 | $5,155 | $34 |
| Exam with injections of chemical for destruction of bladder using an endoscope | 12 | $4,551 | $284 |
| Automated urinalysis test | 1,037 | $4,158 | $2 |
| Destruction and/or removal of growth of bladder and urethra using an endoscope, 2.0-5.0 cm | 15 | $3,735 | $233 |
| Psa (prostate specific antigen) measurement, complexed | 154 | $3,485 | $20 |
| Simple change of bladder tube | 15 | $3,238 | $70 |
| Ultrasound measurement of bladder capacity after voiding | 216 | $2,834 | $10 |
| Complicated insertion of bladder tube | 14 | $2,831 | $109 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 45 | $2,393 | $26 |
| Insertion of temporary bladder tube | 42 | $1,826 | $34 |
| Ultrasonic guidance for needle placement | 31 | $1,758 | $48 |
| Simple insertion of temporary bladder tube | 22 | $1,620 | $46 |
| Insertion of stent in ureter using an endoscope | 14 | $1,562 | $104 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 54 | $1,473 | $17 |
| Simple bladder irrigation and/or instillation | 22 | $1,374 | $55 |
| Injection of drug or substance under skin or into muscle | 40 | $1,087 | $14 |
| Insertion of needle into vein for collection of blood sample | 158 | $529 | $3 |
| Manual urinalysis test with examination using microscope, automated | 18 | $62 | $3 |
| Injection, ceftriaxone sodium, per 250 mg | 26 | $37 | None |
2018: 37 services
| Short return visit (20+ min) | 1,504 | $129,004 | $55 |
| Injection, denosumab, 1 mg | 17 | $120,297 | None |
| Leuprolide acetate (for depot suspension), 7.5 mg | 54 | $61,631 | None |
| Return visit (30+ min) | 537 | $58,203 | $79 |
| Unclassified drugs | 28 | $37,305 | None |
| Diagnostic exam of bladder and urethra using an endoscope | 142 | $21,594 | $129 |
| New patient visit (45+ min) | 153 | $18,153 | $119 |
| Insertion of lower leg neurostimulator electrode | 55 | $16,804 | $108 |
| Removal of prostate gland using an electrocautery knife through urethra with control of bleeding using an endoscope | 21 | $12,479 | $594 |
| New patient visit (30+ min) | 141 | $11,852 | $84 |
| Botox | 12 | $9,168 | None |
| Shock wave crushing of kidney stones | 13 | $5,982 | $460 |
| Psa (prostate specific antigen) measurement, complexed | 222 | $5,843 | $22 |
| Biopsy of prostate gland | 28 | $5,816 | $208 |
| Placement of hormone pellet under skin | 29 | $5,597 | $74 |
| Ultrasound measurement of bladder capacity after voiding | 350 | $5,553 | $12 |
| Automated urinalysis test | 1,168 | $4,996 | $3 |
| Complex measurement of pressure of urine flow in bladder with urethra pressure and voiding pressure studies | 16 | $4,571 | $286 |
| Bcg (intravesical) per instillation | 16 | $4,535 | None |
| Exam with injections of chemical for destruction of bladder using an endoscope | 12 | $4,469 | $263 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 59 | $3,675 | $26 |
| Instillation of anti-cancer drug into bladder | 16 | $2,839 | $71 |
| Simple insertion of temporary bladder tube | 38 | $2,829 | $53 |
| Insertion of device into abdomen with pressure and urine flow rate study | 23 | $2,217 | $96 |
| Insertion of temporary bladder tube | 47 | $2,168 | $39 |
| Simple change of bladder tube | 13 | $1,999 | $77 |
| Injection of drug or substance under skin or into muscle | 54 | $1,950 | $17 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 16 | $1,768 | $110 |
| Ultrasonic guidance for needle placement | 32 | $1,698 | $50 |
| Insertion of stent in ureter using an endoscope | 15 | $1,579 | $105 |
| Short return visit | 32 | $1,420 | $35 |
| Simple bladder irrigation and/or instillation | 16 | $1,410 | $61 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 41 | $1,036 | $18 |
| Non-needle measurement and recording of electrical activity of muscles at bladder and bowel openings | 30 | $900 | $30 |
| Insertion of needle into vein for collection of blood sample | 230 | $800 | $3 |
| Electronic assessment of bladder emptying | 24 | $164 | $7 |
| Injection, ceftriaxone sodium, per 250 mg | 31 | $44 | None |
2017: 37 services
| Short return visit (20+ min) | 1,416 | $143,998 | $62 |
| Injection, denosumab, 1 mg | 15 | $129,265 | None |
| Return visit (30+ min) | 639 | $84,734 | $96 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 64 | $65,984 | None |
| Unclassified drugs | 28 | $37,482 | None |
| Diagnostic exam of bladder and urethra using an endoscope | 147 | $28,653 | $153 |
| Removal of prostate gland using an electrocautery knife through urethra with control of bleeding using an endoscope | 29 | $22,995 | $793 |
| New patient visit (45+ min) | 136 | $19,032 | $140 |
| Insertion of lower leg neurostimulator electrode | 47 | $18,509 | $119 |
| Ultrasound measurement of bladder capacity after voiding | 377 | $9,906 | $18 |
| Psa (prostate specific antigen) measurement, complexed | 301 | $9,175 | $25 |
| Biopsy of prostate gland | 34 | $7,966 | $234 |
| Placement of hormone pellet under skin | 29 | $7,006 | $88 |
| New patient visit (30+ min) | 74 | $6,595 | $89 |
| Complex measurement of pressure of urine flow in bladder with voiding pressure studies | 18 | $5,528 | $307 |
| Automated urinalysis test | 1,092 | $5,389 | $3 |
| Bcg (intravesical) per instillation | 18 | $4,329 | None |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 66 | $4,317 | $32 |
| Injection of drug or substance under skin or into muscle | 67 | $4,235 | $25 |
| Destruction and/or removal of growth of bladder and urethra using an endoscope, 2.0-5.0 cm | 13 | $3,801 | $272 |
| Instillation of anti-cancer drug into bladder | 18 | $3,374 | $82 |
| Simple insertion of temporary bladder tube | 37 | $3,237 | $60 |
| Ultrasound scan of pelvic region through rectum | 33 | $3,075 | $93 |
| Simple change of bladder tube | 18 | $3,046 | $87 |
| Insertion of device into abdomen with pressure and urine flow rate study | 27 | $2,943 | $109 |
| Ultrasonic guidance for needle placement | 39 | $2,505 | $58 |
| Insertion of temporary bladder tube | 40 | $2,498 | $45 |
| Short return visit | 27 | $1,667 | $42 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 11 | $1,663 | $128 |
| Insertion of needle into vein for collection of blood sample | 303 | $1,108 | $3 |
| Insertion of stent in ureter using an endoscope | 11 | $1,090 | $99 |
| Non-needle measurement and recording of electrical activity of muscles at bladder and bowel openings | 27 | $900 | $33 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 13 | $879 | $68 |
| Electronic assessment of bladder emptying | 27 | $205 | $8 |
| Manual urinalysis test with examination using microscope, automated | 22 | $180 | $4 |
| Injection, ceftriaxone sodium, per 250 mg | 29 | $58 | None |
| Injection, garamycin, gentamicin, up to 80 mg | 12 | $24 | None |
2016: 40 services
| Injection, denosumab, 1 mg | 21 | $142,288 | None |
| Short return visit (20+ min) | 1,380 | $127,146 | $54 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 60 | $76,567 | None |
| Return visit (30+ min) | 656 | $73,075 | $80 |
| Diagnostic exam of bladder and urethra using an endoscope | 168 | $33,523 | $167 |
| Unclassified drugs | 20 | $23,226 | None |
| Insertion of lower leg neurostimulator electrode | 48 | $17,872 | $108 |
| New patient visit (45+ min) | 147 | $17,837 | $121 |
| Removal of prostate gland using an electrocautery knife through urethra with control of bleeding using an endoscope | 22 | $15,246 | $693 |
| Psa (prostate specific antigen) measurement, complexed | 293 | $8,721 | $24 |
| Injection, degarelix, 1 mg | 12 | $8,673 | None |
| Biopsy of prostate gland | 49 | $8,569 | $175 |
| Ultrasound measurement of bladder capacity after voiding | 376 | $7,744 | $15 |
| Complex measurement of pressure of urine flow in bladder with voiding pressure studies | 22 | $5,693 | $259 |
| Complex measurement of pressure of urine flow in bladder with urethra pressure and voiding pressure studies | 20 | $5,659 | $283 |
| Bcg (intravesical) per instillation | 25 | $5,354 | None |
| Automated urinalysis test | 1,060 | $5,051 | $3 |
| Simple insertion of temporary bladder tube | 50 | $4,888 | $54 |
| Instillation of anti-cancer drug into bladder | 25 | $4,616 | $81 |
| Non-needle measurement and recording of electrical activity of muscles at bladder and bowel openings | 54 | $4,352 | $81 |
| Placement of hormone pellet under skin | 22 | $4,157 | $77 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 70 | $4,048 | $27 |
| Injection of drug or substance under skin or into muscle | 90 | $4,041 | $21 |
| Insertion of device into abdomen with pressure and urine flow rate study | 42 | $3,947 | $94 |
| Ultrasound scan of pelvic region through rectum | 49 | $3,780 | $77 |
| New patient visit (30+ min) | 44 | $3,713 | $84 |
| Simple change of bladder tube | 18 | $3,531 | $72 |
| Destruction and/or removal of growth of bladder and urethra using an endoscope, 2.0-5.0 cm | 12 | $2,816 | $217 |
| Ultrasonic guidance for needle placement | 52 | $2,807 | $49 |
| Complex measurement of pressure of urine flow in bladder | 12 | $2,659 | $222 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 20 | $2,215 | $111 |
| Insertion of temporary bladder tube | 38 | $1,739 | $41 |
| Simple bladder irrigation and/or instillation | 17 | $1,392 | $66 |
| Insertion of needle into vein for collection of blood sample | 293 | $1,042 | $3 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 14 | $1,033 | $57 |
| Short return visit | 23 | $875 | $30 |
| Manual urinalysis test with examination using microscope, automated | 34 | $279 | $4 |
| Electronic assessment of bladder emptying | 42 | $277 | $7 |
| Injection, ceftriaxone sodium, per 250 mg | 43 | $89 | None |
| Injection, garamycin, gentamicin, up to 80 mg | 13 | $22 | None |
2015: 34 services
| Return visit (30+ min) | 899 | $114,238 | $80 |
| Short return visit (20+ min) | 1,130 | $90,324 | $54 |
| Injection, denosumab, 1 mg | 15 | $87,947 | None |
| Leuprolide acetate (for depot suspension), 7.5 mg | 48 | $65,075 | None |
| Diagnostic exam of bladder and urethra using an endoscope | 149 | $31,938 | $166 |
| Unclassified drugs | 17 | $23,363 | None |
| New patient visit (45+ min) | 161 | $19,606 | $122 |
| Insertion of lower leg neurostimulator electrode | 32 | $15,333 | $102 |
| Psa (prostate specific antigen) measurement, complexed | 321 | $10,041 | $24 |
| Biopsy of prostate gland | 38 | $6,369 | $168 |
| Simple insertion of temporary bladder tube | 61 | $5,853 | $57 |
| Ultrasound measurement of bladder capacity after voiding | 277 | $5,488 | $15 |
| Automated urinalysis test | 998 | $4,753 | $3 |
| Placement of hormone pellet under skin | 19 | $4,297 | $77 |
| Simple change of bladder tube | 23 | $3,645 | $76 |
| Bcg (intravesical) per instillation | 15 | $3,442 | None |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 55 | $3,410 | $27 |
| Instillation of anti-cancer drug into bladder | 15 | $3,184 | $88 |
| Complex measurement of pressure of urine flow in bladder with voiding pressure studies | 12 | $3,156 | $263 |
| Injection of drug or substance under skin or into muscle | 76 | $3,122 | $21 |
| Ultrasound scan of pelvic region through rectum | 37 | $2,877 | $78 |
| Non-needle measurement and recording of electrical activity of muscles at bladder and bowel openings | 26 | $2,101 | $81 |
| Ultrasonic guidance for needle placement | 39 | $2,084 | $50 |
| Insertion of device into abdomen with pressure and urine flow rate study | 21 | $1,964 | $94 |
| Insertion of temporary bladder tube | 35 | $1,957 | $43 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 15 | $1,374 | $57 |
| Simple bladder irrigation and/or instillation | 18 | $1,358 | $68 |
| New patient visit (30+ min) | 17 | $1,353 | $80 |
| Insertion of needle into vein for collection of blood sample | 321 | $1,203 | $3 |
| Short return visit | 11 | $434 | $36 |
| Manual urinalysis test with examination using microscope, automated | 47 | $300 | $4 |
| Electronic assessment of bladder emptying | 21 | $139 | $7 |
| Injection, ceftriaxone sodium, per 250 mg | 36 | $87 | None |
| Injection, garamycin, gentamicin, up to 80 mg | 17 | $37 | None |
2014: 32 services
| Return visit (30+ min) | 743 | $91,605 | $83 |
| Short return visit (20+ min) | 1,057 | $87,465 | $55 |
| Injection, denosumab, 1 mg | 11 | $78,381 | None |
| Leuprolide acetate (for depot suspension), 7.5 mg | 47 | $52,506 | None |
| Diagnostic exam of bladder and urethra using an endoscope | 168 | $34,096 | $162 |
| New patient visit (45+ min) | 161 | $20,522 | $127 |
| Unclassified drugs | 14 | $11,407 | None |
| Psa (prostate specific antigen) measurement, complexed | 313 | $9,865 | $24 |
| Ultrasound measurement of bladder capacity after voiding | 329 | $6,560 | $16 |
| Complex measurement of pressure of urine flow in bladder with voiding pressure studies | 25 | $6,193 | $248 |
| Automated urinalysis test | 993 | $5,073 | $3 |
| Simple insertion of temporary bladder tube | 39 | $4,232 | $57 |
| Biopsy of prostate gland | 23 | $3,954 | $172 |
| Instillation of anti-cancer drug into bladder | 15 | $2,970 | $85 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 51 | $2,958 | $27 |
| Destruction and/or removal of growth of bladder and urethra using an endoscope, 2.0-5.0 cm | 12 | $2,899 | $223 |
| Bcg (intravesical) per instillation | 11 | $2,612 | None |
| New patient visit (30+ min) | 31 | $2,589 | $84 |
| Injection of drug or substance under skin or into muscle | 51 | $2,452 | $21 |
| Placement of hormone pellet under skin | 16 | $2,422 | $78 |
| Insertion of device into abdomen with pressure and urine flow rate study | 25 | $2,209 | $88 |
| Ultrasonic guidance for needle placement | 24 | $1,776 | $61 |
| Ultrasound scan of pelvic region through rectum | 22 | $1,619 | $74 |
| Non-needle measurement and recording of electrical activity of muscles at bladder and bowel openings | 20 | $1,538 | $77 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 14 | $1,538 | $110 |
| Insertion of needle into vein for collection of blood sample | 312 | $1,174 | $3 |
| Insertion of stent in ureter using an endoscope | 13 | $1,014 | $78 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 11 | $916 | $57 |
| Insertion of temporary bladder tube | 15 | $455 | $30 |
| Manual urinalysis test with examination using microscope, automated | 46 | $271 | $4 |
| Electronic assessment of bladder emptying | 26 | $174 | $7 |
| Injection, ceftriaxone sodium, per 250 mg | 24 | $58 | None |
2013: 31 services
| Short return visit (20+ min) | 1,473 | $140,931 | $54 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 71 | $68,629 | None |
| Injection, denosumab, 1 mg | 14 | $55,679 | None |
| Return visit (30+ min) | 451 | $48,336 | $80 |
| Diagnostic exam of bladder and urethra using an endoscope | 205 | $39,497 | $164 |
| New patient visit (45+ min) | 133 | $16,617 | $125 |
| Psa (prostate specific antigen) measurement, complexed | 394 | $12,768 | $25 |
| Ultrasound measurement of bladder capacity after voiding | 540 | $12,057 | $15 |
| Removal of prostate gland using an electrocautery knife through urethra with control of bleeding using an endoscope | 15 | $9,905 | $660 |
| New patient visit (30+ min) | 116 | $9,299 | $80 |
| Automated urinalysis test | 1,265 | $7,215 | $3 |
| Simple insertion of temporary bladder tube | 63 | $7,039 | $55 |
| Complex measurement of pressure of urine flow in bladder with voiding pressure studies | 28 | $6,938 | $239 |
| Ultrasonic guidance for needle placement | 35 | $6,937 | $173 |
| Biopsy of prostate gland | 32 | $5,660 | $177 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 71 | $3,048 | $26 |
| Simple change of bladder tube | 17 | $2,869 | $70 |
| Injection of drug or substance under skin or into muscle | 55 | $2,538 | $21 |
| Short return visit | 54 | $2,427 | $36 |
| Insertion of device into abdomen with pressure and urine flow rate study | 28 | $2,404 | $86 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 18 | $1,974 | $56 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 18 | $1,936 | $108 |
| Non-needle measurement and recording of electrical activity of muscles at bladder and bowel openings | 24 | $1,761 | $73 |
| Insertion of needle into vein for collection of blood sample | 394 | $1,524 | $3 |
| Ultrasound scan of pelvic region through rectum | 23 | $1,397 | $61 |
| Simple bladder irrigation and/or instillation | 12 | $1,162 | $68 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 26 | $679 | $17 |
| Insertion of temporary bladder tube | 16 | $569 | $26 |
| Electronic assessment of bladder emptying | 29 | $178 | $6 |
| Manual urinalysis test with examination using microscope, automated | 22 | $145 | $4 |
| Injection, garamycin, gentamicin, up to 80 mg | 22 | $42 | None |
Medicaid work
$8,070 in 2024
Medicaid paid $8,070 for 297 billed services this clinician did in 2024, up to 29 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 123 | $6,235 |
| Short return visit (20+ min) | 41 | $1,568 |
| Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any number of these constituents; automated, without microscopy | 117 | $176 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | 16 | $91 |
| 2024 | 297 | 4 | 29 | $8,070 |
| 2023 | 724 | 4 | 40 | $12,927 |
| 2022 | 415 | 3 | 26 | $9,113 |
| 2021 | 649 | 3 | 37 | $15,904 |
| 2020 | 484 | 2 | 31 | $8,312 |
| 2019 | 191 | 2 | 22 | $2,556 |
| 2018 | 125 | 2 | 15 | $2,807 |
See the largest Medicaid services in earlier years
2023
| Return visit (30+ min) | 240 | $9,318 |
| Short return visit (20+ min) | 127 | $2,851 |
| Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any number of these constituents; automated, without microscopy | 343 | $416 |
| Measurement of post-voiding residual urine and/or bladder capacity by ultrasound, non-imaging | 14 | $341 |
2022
| Short return visit (20+ min) | 121 | $5,097 |
| Return visit (30+ min) | 76 | $3,762 |
| Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any number of these constituents; automated, without microscopy | 218 | $254 |
2021
| Short return visit (20+ min) | 239 | $10,101 |
| Return visit (30+ min) | 93 | $5,405 |
| Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any number of these constituents; automated, without microscopy | 317 | $398 |
2020
| Short return visit (20+ min) | 245 | $8,015 |
| Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any number of these constituents; automated, without microscopy | 239 | $297 |
2019
| Short return visit (20+ min) | 100 | $2,363 |
| Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any number of these constituents; automated, without microscopy | 91 | $193 |
2018
| Short return visit (20+ min) | 86 | $2,706 |
| Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any number of these constituents; automated, without microscopy | 39 | $101 |
Drugs they prescribed that Part D paid
$2,197,665
Pharmacies billed $2,197,665 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 2% of their Part D prescriptions (113 of 5,024) in 2024. Above the middle of the specialty; the typical urology clinician is at 2%.
4,295 generic and 708 brand-name prescriptions · $2,197,665 in drug cost · 285 antibiotic prescriptions to 155 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Xtandi | 63 | $852,610 | $13,533 |
| Erleada | 25 | $361,323 | $14,453 |
| Myrbetriq | 254 | $218,733 | $861 |
| Orgovyx | 83 | $214,653 | $2,586 |
| Nubeqa | 13 | $177,359 | $13,643 |
See all 41 drugs
| Xtandi | 63 | $852,610 | $13,533 |
| Erleada | 25 | $361,323 | $14,453 |
| Myrbetriq | 254 | $218,733 | $861 |
| Orgovyx | 83 | $214,653 | $2,586 |
| Nubeqa | 13 | $177,359 | $13,643 |
| Gemtesa | 167 | $155,912 | $934 |
| Elmiron | 18 | $30,724 | $1,707 |
| Finasteride | 1,281 | $21,663 | $17 |
| Testosterone | 141 | $20,966 | $149 |
| Tamsulosin | 812 | $16,863 | $21 |
| Mirabegron Er | 25 | $16,046 | $642 |
| Silodosin | 133 | $15,291 | $115 |
| Alfuzosin Hcl Er | 416 | $9,826 | $24 |
| Dutasteride | 212 | $9,406 | $44 |
| Premarin | 19 | $8,197 | $431 |
| Methenamine Hippurate | 70 | $8,195 | $117 |
| Potassium Citrate Er | 45 | $6,486 | $144 |
| Estradiol | 109 | $6,479 | $59 |
| Solifenacin | 153 | $4,626 | $30 |
| Abiraterone Acetate | 29 | $4,605 | $159 |
| Trospium Chloride | 99 | $3,214 | $32 |
| Nitrofurantoin Mono-Macro | 72 | $2,283 | $32 |
| Methenamine Mandelate | 13 | $2,167 | $167 |
| Trimethoprim | 33 | $1,861 | $56 |
| Hydroxyzine | 30 | $1,468 | $49 |
| Oxybutynin Chloride Er | 41 | $1,161 | $28 |
| Oxybutynin Chloride | 25 | $1,055 | $42 |
| Tadalafil | 23 | $1,002 | $44 |
| Terazosin | 33 | $590 | $18 |
| Nitrofurantoin | 24 | $559 | $23 |
| Bicalutamide | 22 | $476 | $22 |
| Amitriptyline | 40 | $406 | $10 |
| Doxazosin Mesylate | 18 | $316 | $18 |
| Gabapentin | 11 | $293 | $27 |
| Sildenafil Citrate | 36 | $270 | $8 |
| Levofloxacin | 77 | $214 | $3 |
| Prednisone | 29 | $204 | $7 |
| Amoxicillin-Clavulanate Potass | 13 | $166 | $13 |
| Sulfamethoxazole-Trimethoprim | 36 | $134 | $4 |
| Tramadol | 107 | $134 | $1 |
| Cephalexin | 15 | $114 | $8 |
Year by year
| 2024 | 5,024 | 1,078 | 2% (113) | 14% | $2,197,665 |
| 2023 | 4,791 | 1,112 | 3% (127) | 13% | $1,515,932 |
| 2022 | 4,577 | 1,010 | 3% (124) | 15% | $1,555,743 |
| 2021 | 4,198 | 960 | 3% (130) | 17% | $2,068,336 |
| 2020 | 4,074 | 910 | 2% (94) | 19% | $1,276,900 |
| 2019 | 3,953 | 930 | 3% (106) | 23% | $1,015,849 |
| 2018 | 3,977 | 918 | 2% (90) | 25% | $1,269,083 |
| 2017 | 4,166 | 901 | 2% (93) | 25% | $818,757 |
| 2016 | 4,138 | 828 | 3% (103) | None | $1,413,378 |
| 2015 | 3,765 | 764 | 2% (73) | 40% | $1,489,315 |
| 2014 | 3,412 | 716 | 2% (80) | 43% | $727,393 |
| 2013 | 3,585 | 778 | 3% (91) | 38% | $462,222 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 42 drugs
| Xtandi | 33 | $489,931 | $14,846 |
| Erleada | 26 | $389,695 | $14,988 |
| Myrbetriq | 321 | $283,507 | $883 |
| Gemtesa | 103 | $92,079 | $894 |
| Orgovyx | 12 | $31,419 | $2,618 |
| Tamsulosin | 833 | $25,405 | $30 |
| Elmiron | 18 | $24,503 | $1,361 |
| Finasteride | 1,206 | $24,359 | $20 |
| Testosterone | 119 | $19,142 | $161 |
| Dutasteride | 210 | $13,382 | $64 |
| Silodosin | 100 | $12,626 | $126 |
| Alfuzosin Hcl Er | 357 | $10,070 | $28 |
| Premarin | 22 | $9,654 | $439 |
| Methenamine Hippurate | 53 | $8,020 | $151 |
| Potassium Citrate Er | 44 | $7,985 | $181 |
| Estradiol | 85 | $6,754 | $79 |
| Solifenacin | 128 | $6,494 | $51 |
| Abiraterone Acetate | 11 | $5,880 | $535 |
| Trospium Chloride | 99 | $4,097 | $41 |
| Methenamine Mandelate | 27 | $3,515 | $130 |
| Nitrofurantoin Mono-Macro | 98 | $2,789 | $28 |
| Hydroxyzine | 30 | $1,739 | $58 |
| Trimethoprim | 27 | $1,692 | $63 |
| Oxybutynin Chloride Er | 32 | $1,680 | $53 |
| Tadalafil | 11 | $1,098 | $100 |
| Terazosin | 30 | $1,013 | $34 |
| Oxybutynin Chloride | 31 | $879 | $28 |
| Nitrofurantoin | 20 | $852 | $43 |
| Doxazosin Mesylate | 19 | $587 | $31 |
| Sulfamethoxazole-Trimethoprim | 76 | $562 | $7 |
| Bicalutamide | 20 | $420 | $21 |
| Levofloxacin | 111 | $332 | $3 |
| Amitriptyline | 24 | $296 | $12 |
| Cephalexin | 37 | $292 | $8 |
| Ciprofloxacin | 28 | $252 | $9 |
| Sildenafil Citrate | 22 | $212 | $10 |
| Amoxicillin-Clavulanate Potass | 19 | $205 | $11 |
| Prednisone | 14 | $194 | $14 |
| Tramadol | 114 | $166 | $1 |
| Triamcinolone Acetonide | 13 | $73 | $6 |
| Hydrocodone-Acetaminophen | 12 | $65 | $5 |
| Amoxicillin | 15 | $55 | $4 |
2022: 45 drugs
| Xtandi | 46 | $623,809 | $13,561 |
| Myrbetriq | 377 | $322,003 | $854 |
| Erleada | 20 | $286,959 | $14,348 |
| Gemtesa | 39 | $28,027 | $719 |
| Finasteride | 1,183 | $22,685 | $19 |
| Tamsulosin | 772 | $20,933 | $27 |
| Dutasteride | 249 | $18,377 | $74 |
| Testosterone | 77 | $13,059 | $170 |
| Silodosin | 77 | $12,263 | $159 |
| Alfuzosin Hcl Er | 294 | $8,960 | $30 |
| Premarin | 20 | $8,515 | $426 |
| Methenamine Hippurate | 42 | $7,502 | $179 |
| Solifenacin | 128 | $7,434 | $58 |
| Estradiol | 72 | $7,331 | $102 |
| Darifenacin Er | 14 | $6,709 | $479 |
| Nocdurna | 11 | $5,845 | $531 |
| Toviaz | 33 | $5,304 | $161 |
| Trospium Chloride | 77 | $4,967 | $65 |
| Potassium Citrate Er | 23 | $3,839 | $167 |
| Nitrofurantoin Mono-Macro | 61 | $3,391 | $56 |
| Avodart | 12 | $2,979 | $248 |
| Trimethoprim | 35 | $2,576 | $74 |
| Fosfomycin Tromethamine | 12 | $2,192 | $183 |
| Oxybutynin Chloride | 52 | $2,142 | $41 |
| Oxybutynin Chloride Er | 43 | $1,954 | $45 |
| Terazosin | 41 | $1,545 | $38 |
| Nitrofurantoin | 22 | $1,121 | $51 |
| Methenamine Mandelate | 13 | $1,121 | $86 |
| Hydroxyzine | 44 | $876 | $20 |
| Doxazosin Mesylate | 18 | $752 | $42 |
| Megestrol Acetate | 12 | $622 | $52 |
| Chlorthalidone | 14 | $440 | $31 |
| Sulfamethoxazole-Trimethoprim | 75 | $373 | $5 |
| Allopurinol | 19 | $333 | $18 |
| Sildenafil Citrate | 16 | $332 | $21 |
| Tadalafil | 22 | $273 | $12 |
| Cephalexin | 51 | $262 | $5 |
| Amoxicillin-Clavulanate Potass | 27 | $262 | $10 |
| Ciprofloxacin | 34 | $258 | $8 |
| Cefdinir | 16 | $215 | $13 |
| Levofloxacin | 75 | $199 | $3 |
| Tramadol | 112 | $175 | $2 |
| Ciclopirox | 15 | $143 | $10 |
| Amoxicillin | 21 | $83 | $4 |
| Triamcinolone Acetonide | 13 | $59 | $5 |
2021: 39 drugs
| Erleada | 54 | $738,931 | $13,684 |
| Xtandi | 52 | $644,330 | $12,391 |
| Myrbetriq | 374 | $283,170 | $757 |
| Abiraterone Acetate | 31 | $188,552 | $6,082 |
| Finasteride | 1,042 | $22,992 | $22 |
| Tamsulosin | 756 | $17,266 | $23 |
| Premarin | 40 | $16,311 | $408 |
| Dutasteride | 265 | $13,942 | $53 |
| Toviaz | 61 | $13,102 | $215 |
| Testosterone | 64 | $12,022 | $188 |
| Methenamine Hippurate | 58 | $9,709 | $167 |
| Silodosin | 67 | $8,326 | $124 |
| Alfuzosin Hcl Er | 195 | $7,903 | $41 |
| Darifenacin Er | 20 | $7,751 | $388 |
| Potassium Citrate Er | 42 | $6,611 | $157 |
| Solifenacin | 73 | $5,214 | $71 |
| Trospium Chloride | 67 | $4,759 | $71 |
| Estradiol | 34 | $3,892 | $114 |
| Nitrofurantoin Mono-Macro | 60 | $3,747 | $62 |
| Oxybutynin Chloride | 50 | $2,081 | $42 |
| Methenamine Mandelate | 17 | $1,428 | $84 |
| Doxazosin Mesylate | 47 | $1,258 | $27 |
| Trimethoprim | 25 | $1,062 | $42 |
| Tadalafil | 27 | $964 | $36 |
| Oxybutynin Chloride Er | 34 | $913 | $27 |
| Terazosin | 33 | $879 | $27 |
| Hydroxyzine | 36 | $564 | $16 |
| Chlorthalidone | 16 | $511 | $32 |
| Testosterone Cypionate | 11 | $434 | $39 |
| Allopurinol | 14 | $304 | $22 |
| Prednisone | 24 | $292 | $12 |
| Levofloxacin | 81 | $259 | $3 |
| Tramadol | 120 | $253 | $2 |
| Sulfamethoxazole-Trimethoprim | 46 | $180 | $4 |
| Cefdinir | 12 | $154 | $13 |
| Cephalexin | 25 | $154 | $6 |
| Ciprofloxacin | 20 | $147 | $7 |
| Phenazopyridine | 11 | $125 | $11 |
| Amoxicillin | 18 | $80 | $4 |
2020: 42 drugs
| Erleada | 27 | $348,549 | $12,909 |
| Myrbetriq | 435 | $305,553 | $702 |
| Xtandi | 23 | $277,982 | $12,086 |
| Abiraterone Acetate | 18 | $95,808 | $5,323 |
| Toviaz | 78 | $30,963 | $397 |
| Finasteride | 976 | $21,680 | $22 |
| Testosterone | 82 | $17,397 | $212 |
| Dutasteride | 242 | $16,035 | $66 |
| Tamsulosin | 715 | $15,899 | $22 |
| Silodosin | 101 | $15,796 | $156 |
| Darifenacin Er | 32 | $12,621 | $394 |
| Rapaflo | 17 | $12,092 | $711 |
| Premarin | 29 | $11,472 | $396 |
| Cialis | 12 | $10,205 | $850 |
| Methenamine Hippurate | 66 | $8,374 | $127 |
| Alfuzosin Hcl Er | 169 | $6,747 | $40 |
| Solifenacin | 44 | $5,085 | $116 |
| Potassium Citrate Er | 26 | $4,144 | $159 |
| Trospium Chloride | 55 | $4,110 | $75 |
| Nitrofurantoin Mono-Macro | 75 | $3,873 | $52 |
| Monurol | 23 | $3,317 | $144 |
| Estradiol | 19 | $2,977 | $157 |
| Tadalafil | 21 | $2,930 | $140 |
| Oxybutynin Chloride | 53 | $1,908 | $36 |
| Methenamine Mandelate | 14 | $1,456 | $104 |
| Trimethoprim | 49 | $1,350 | $28 |
| Oxybutynin Chloride Er | 13 | $948 | $73 |
| Doxazosin Mesylate | 41 | $917 | $22 |
| Nitrofurantoin | 15 | $742 | $49 |
| Terazosin | 27 | $706 | $26 |
| Sulfamethoxazole-Trimethoprim | 94 | $432 | $5 |
| Hydroxyzine | 30 | $392 | $13 |
| Levofloxacin | 79 | $326 | $4 |
| Phenazopyridine | 14 | $260 | $19 |
| Tramadol | 88 | $160 | $2 |
| Allopurinol | 12 | $153 | $13 |
| Amitriptyline | 12 | $141 | $12 |
| Ciprofloxacin | 21 | $132 | $6 |
| Cephalexin | 36 | $129 | $4 |
| Prednisone | 18 | $96 | $5 |
| Amoxicillin | 17 | $65 | $4 |
| Triamcinolone Acetonide | 11 | $37 | $3 |
2019: 40 drugs
| Myrbetriq | 484 | $313,639 | $648 |
| Erleada | 15 | $186,553 | $12,437 |
| Abiraterone Acetate | 12 | $75,353 | $6,279 |
| Toviaz | 108 | $41,957 | $388 |
| Vesicare | 42 | $26,260 | $625 |
| Testosterone | 52 | $23,533 | $453 |
| Dutasteride | 245 | $22,629 | $92 |
| Finasteride | 876 | $21,093 | $24 |
| Tamsulosin | 733 | $17,280 | $24 |
| Elmiron | 13 | $15,298 | $1,177 |
| Cialis | 18 | $14,938 | $830 |
| Tadalafil | 40 | $14,711 | $368 |
| Premarin | 38 | $14,136 | $372 |
| Darifenacin Er | 36 | $12,454 | $346 |
| Silodosin | 83 | $11,395 | $137 |
| Rapaflo | 15 | $9,112 | $607 |
| Methenamine Hippurate | 49 | $6,744 | $138 |
| Alfuzosin Hcl Er | 145 | $5,486 | $38 |
| Solifenacin | 32 | $5,298 | $166 |
| Estradiol | 29 | $5,236 | $181 |
| Potassium Citrate Er | 34 | $4,047 | $119 |
| Nitrofurantoin Mono-Macro | 53 | $2,422 | $46 |
| Oxybutynin Chloride | 55 | $2,319 | $42 |
| Trimethoprim | 72 | $1,576 | $22 |
| Trospium Chloride | 26 | $1,532 | $59 |
| Oxybutynin Chloride Er | 27 | $1,091 | $40 |
| Nitrofurantoin | 20 | $969 | $48 |
| Megestrol Acetate | 13 | $669 | $51 |
| Doxazosin Mesylate | 25 | $655 | $26 |
| Terazosin | 31 | $563 | $18 |
| Chlorthalidone | 11 | $508 | $46 |
| Sulfamethoxazole-Trimethoprim | 73 | $464 | $6 |
| Hydroxyzine | 21 | $341 | $16 |
| Amitriptyline | 12 | $294 | $25 |
| Tramadol | 98 | $289 | $3 |
| Gabapentin | 11 | $283 | $26 |
| Levofloxacin | 63 | $276 | $4 |
| Cephalexin | 39 | $248 | $6 |
| Ciprofloxacin | 29 | $158 | $5 |
| Amoxicillin | 14 | $62 | $4 |
2018: 38 drugs
| Zytiga | 34 | $344,070 | $10,120 |
| Myrbetriq | 400 | $248,456 | $621 |
| Xtandi | 26 | $237,366 | $9,129 |
| Toviaz | 110 | $45,285 | $412 |
| Cialis | 57 | $39,162 | $687 |
| Rapaflo | 72 | $35,595 | $494 |
| Vesicare | 54 | $35,277 | $653 |
| Tamsulosin | 806 | $23,227 | $29 |
| Androgel | 14 | $21,575 | $1,541 |
| Dutasteride | 307 | $18,759 | $61 |
| Finasteride | 820 | $18,299 | $22 |
| Darifenacin Er | 36 | $14,293 | $397 |
| Testosterone | 20 | $9,828 | $491 |
| Methenamine Hippurate | 56 | $8,781 | $157 |
| Premarin | 23 | $8,209 | $357 |
| Dutasteride-Tamsulosin | 27 | $7,936 | $294 |
| Potassium Citrate Er | 37 | $7,203 | $195 |
| Tolterodine Tartrate Er | 20 | $6,315 | $316 |
| Estradiol | 23 | $4,113 | $179 |
| Alfuzosin Hcl Er | 127 | $4,031 | $32 |
| Oxybutynin Chloride | 78 | $2,931 | $38 |
| Nitrofurantoin Mono-Macro | 38 | $1,938 | $51 |
| Nitrofurantoin | 37 | $1,938 | $52 |
| Trimethoprim | 72 | $1,774 | $25 |
| Oxybutynin Chloride Er | 35 | $1,620 | $46 |
| Trospium Chloride | 11 | $1,164 | $106 |
| Doxazosin Mesylate | 30 | $1,084 | $36 |
| Hydroxyzine | 22 | $1,058 | $48 |
| Terazosin | 51 | $859 | $17 |
| Gabapentin | 22 | $717 | $33 |
| Bicalutamide | 17 | $659 | $39 |
| Amitriptyline | 28 | $636 | $23 |
| Sulfamethoxazole-Trimethoprim | 63 | $452 | $7 |
| Cephalexin | 44 | $330 | $7 |
| Ciprofloxacin | 37 | $257 | $7 |
| Levofloxacin | 49 | $250 | $5 |
| Tramadol | 79 | $188 | $2 |
| Prednisone | 20 | $182 | $9 |
2017: 42 drugs
| Myrbetriq | 390 | $216,508 | $555 |
| Xtandi | 14 | $136,023 | $9,716 |
| Vesicare | 85 | $41,724 | $491 |
| Elmiron | 23 | $34,660 | $1,507 |
| Rapaflo | 93 | $34,317 | $369 |
| Toviaz | 71 | $33,786 | $476 |
| Tamsulosin | 842 | $31,079 | $37 |
| Cialis | 47 | $29,841 | $635 |
| Dutasteride | 316 | $27,404 | $87 |
| Androgel | 24 | $23,369 | $974 |
| Finasteride | 803 | $16,928 | $21 |
| Dutasteride-Tamsulosin | 47 | $15,303 | $326 |
| Tolterodine Tartrate Er | 50 | $13,408 | $268 |
| Estrace | 40 | $11,370 | $284 |
| Darifenacin Er | 26 | $9,367 | $360 |
| Methenamine Hippurate | 77 | $9,000 | $117 |
| Premarin | 15 | $6,206 | $414 |
| Nitrofurantoin | 79 | $4,407 | $56 |
| Potassium Citrate Er | 21 | $3,624 | $173 |
| Avodart | 14 | $3,566 | $255 |
| Alfuzosin Hcl Er | 139 | $3,456 | $25 |
| Oxybutynin Chloride | 67 | $3,372 | $50 |
| Trospium Chloride | 35 | $2,421 | $69 |
| Nitrofurantoin Mono-Macro | 27 | $1,887 | $70 |
| Trimethoprim | 70 | $1,644 | $23 |
| Megestrol Acetate | 17 | $1,355 | $80 |
| Doxazosin Mesylate | 38 | $1,231 | $32 |
| Bicalutamide | 24 | $1,010 | $42 |
| Terazosin | 60 | $764 | $13 |
| Gabapentin | 24 | $702 | $29 |
| Amitriptyline | 26 | $585 | $22 |
| Sulfamethoxazole-Trimethoprim | 94 | $558 | $6 |
| Hydroxyzine | 18 | $516 | $29 |
| Ciprofloxacin | 65 | $478 | $7 |
| Levofloxacin | 56 | $433 | $8 |
| Fluconazole | 17 | $323 | $19 |
| Cephalexin | 46 | $255 | $6 |
| Tramadol | 76 | $250 | $3 |
| Triamcinolone Acetonide | 16 | $109 | $7 |
| Atorvastatin | 11 | $67 | $6 |
| Hydrocodone-Acetaminophen | 13 | $65 | $5 |
| Amoxicillin | 14 | $46 | $3 |
2016: 46 drugs
| Xtandi | 50 | $477,321 | $9,546 |
| Zytiga | 37 | $353,162 | $9,545 |
| Myrbetriq | 369 | $181,462 | $492 |
| Androgel | 35 | $40,820 | $1,166 |
| Vesicare | 63 | $36,498 | $579 |
| Rapaflo | 103 | $34,592 | $336 |
| Toviaz | 71 | $33,139 | $467 |
| Dutasteride | 308 | $32,929 | $107 |
| Tamsulosin | 848 | $32,522 | $38 |
| Cialis | 47 | $21,931 | $467 |
| Avodart | 68 | $20,380 | $300 |
| Elmiron | 25 | $19,919 | $797 |
| Finasteride | 760 | $16,122 | $21 |
| Methenamine Hippurate | 85 | $14,133 | $166 |
| Tolterodine Tartrate Er | 44 | $11,306 | $257 |
| Dutasteride-Tamsulosin | 35 | $9,895 | $283 |
| Enablex | 12 | $9,028 | $752 |
| Estrace | 34 | $8,974 | $264 |
| Darifenacin Er | 16 | $7,364 | $460 |
| Jalyn | 19 | $5,828 | $307 |
| Trospium Chloride Er | 13 | $5,756 | $443 |
| Nitrofurantoin | 68 | $4,274 | $63 |
| Potassium Citrate Er | 25 | $4,006 | $160 |
| Oxybutynin Chloride | 61 | $2,888 | $47 |
| Trimethoprim | 95 | $2,261 | $24 |
| Alfuzosin Hcl Er | 89 | $2,119 | $24 |
| Trospium Chloride | 19 | $2,103 | $111 |
| Nitrofurantoin Mono-Macro | 15 | $1,554 | $104 |
| Bicalutamide | 30 | $1,278 | $43 |
| Doxycycline Hyclate | 20 | $1,131 | $57 |
| Gabapentin | 24 | $818 | $34 |
| Sulfamethoxazole-Trimethoprim | 97 | $587 | $6 |
| Amitriptyline | 24 | $436 | $18 |
| Oxybutynin Chloride Er | 13 | $422 | $32 |
| Terazosin | 30 | $390 | $13 |
| Prednisone | 31 | $352 | $11 |
| Levofloxacin | 63 | $343 | $5 |
| Ciprofloxacin | 38 | $303 | $8 |
| Hydroxyzine | 20 | $299 | $15 |
| Doxazosin Mesylate | 17 | $265 | $16 |
| Hydrocodone-Acetaminophen | 26 | $261 | $10 |
| Tramadol | 71 | $257 | $4 |
| Pentoxifylline | 13 | $206 | $16 |
| Cephalexin | 27 | $190 | $7 |
| Amoxicillin | 35 | $140 | $4 |
| Triamcinolone Acetonide | 18 | $74 | $4 |
2015: 44 drugs
| Xtandi | 59 | $577,642 | $9,791 |
| Zytiga | 36 | $296,091 | $8,225 |
| Myrbetriq | 302 | $145,592 | $482 |
| Avodart | 325 | $103,888 | $320 |
| Toviaz | 97 | $41,189 | $425 |
| Rapaflo | 130 | $37,295 | $287 |
| Elmiron | 37 | $35,737 | $966 |
| Vesicare | 61 | $31,954 | $524 |
| Tamsulosin | 643 | $29,495 | $46 |
| Jalyn | 89 | $27,005 | $303 |
| Androgel | 25 | $19,490 | $780 |
| Enablex | 27 | $16,999 | $630 |
| Methenamine Hippurate | 96 | $15,902 | $166 |
| Cialis | 43 | $15,332 | $357 |
| Finasteride | 647 | $13,996 | $22 |
| Tolterodine Tartrate Er | 37 | $10,072 | $272 |
| Potassium Citrate Er | 53 | $8,225 | $155 |
| Premarin | 26 | $7,657 | $294 |
| Estrace | 29 | $6,342 | $219 |
| Dutasteride | 24 | $5,205 | $217 |
| Nitrofurantoin | 71 | $4,059 | $57 |
| Trospium Chloride | 22 | $3,103 | $141 |
| Oxybutynin Chloride | 42 | $2,260 | $54 |
| Nitrofurantoin Mono-Macro | 29 | $2,167 | $75 |
| Trimethoprim | 57 | $1,439 | $25 |
| Oxybutynin Chloride Er | 24 | $1,438 | $60 |
| Alfuzosin Hcl Er | 58 | $1,366 | $24 |
| Hydroxyzine | 48 | $1,193 | $25 |
| Gabapentin | 25 | $1,157 | $46 |
| Bicalutamide | 18 | $886 | $49 |
| Amitriptyline | 23 | $761 | $33 |
| Doxazosin Mesylate | 30 | $652 | $22 |
| Megestrol Acetate | 19 | $617 | $32 |
| Terazosin | 48 | $533 | $11 |
| Ciprofloxacin | 62 | $455 | $7 |
| Sulfamethoxazole-Trimethoprim | 74 | $451 | $6 |
| Pentoxifylline | 16 | $449 | $28 |
| Levofloxacin | 45 | $385 | $9 |
| Hydrocodone-Acetaminophen | 14 | $366 | $26 |
| Prednisone | 37 | $354 | $10 |
| Tramadol | 55 | $200 | $4 |
| Cephalexin | 27 | $172 | $6 |
| Triamcinolone Acetonide | 17 | $63 | $4 |
| Amoxicillin | 17 | $60 | $4 |
2014: 40 drugs
| Zytiga | 18 | $127,369 | $7,076 |
| Myrbetriq | 248 | $99,849 | $403 |
| Avodart | 332 | $93,245 | $281 |
| Toviaz | 136 | $45,805 | $337 |
| Vesicare | 69 | $32,908 | $477 |
| Rapaflo | 106 | $24,613 | $232 |
| Elmiron | 25 | $23,078 | $923 |
| Jalyn | 100 | $22,268 | $223 |
| Enablex | 60 | $20,377 | $340 |
| Tamsulosin | 594 | $18,129 | $31 |
| Methenamine Hippurate | 119 | $17,847 | $150 |
| Androgel | 17 | $17,841 | $1,049 |
| Finasteride | 498 | $12,038 | $24 |
| Potassium Citrate Er | 64 | $10,193 | $159 |
| Cialis | 30 | $7,316 | $244 |
| Fortesta | 16 | $7,234 | $452 |
| Estrace | 28 | $4,607 | $165 |
| Nitrofurantoin | 57 | $4,286 | $75 |
| Nitrofurantoin Mono-Macro | 52 | $3,415 | $66 |
| Premarin | 11 | $3,179 | $289 |
| Trospium Chloride | 19 | $2,957 | $156 |
| Doxycycline Hyclate | 18 | $1,963 | $109 |
| Trimethoprim | 74 | $1,923 | $26 |
| Oxybutynin Chloride | 39 | $1,792 | $46 |
| Oxybutynin Chloride Er | 16 | $1,453 | $91 |
| Alfuzosin Hcl Er | 42 | $1,397 | $33 |
| Bicalutamide | 24 | $1,308 | $55 |
| Gabapentin | 22 | $906 | $41 |
| Hydroxyzine | 42 | $759 | $18 |
| Terazosin | 48 | $591 | $12 |
| Amitriptyline | 17 | $504 | $30 |
| Sulfamethoxazole-Trimethoprim | 88 | $465 | $5 |
| Doxazosin Mesylate | 12 | $447 | $37 |
| Levofloxacin | 52 | $367 | $7 |
| Tramadol | 63 | $258 | $4 |
| Ciprofloxacin | 36 | $173 | $5 |
| Prednisone | 18 | $173 | $10 |
| Cephalexin | 26 | $116 | $4 |
| Hydrocodone-Acetaminophen | 13 | $102 | $8 |
| Amoxicillin | 21 | $81 | $4 |
2013: 35 drugs
| Avodart | 329 | $82,765 | $252 |
| Toviaz | 180 | $48,865 | $271 |
| Myrbetriq | 133 | $46,858 | $352 |
| Elmiron | 39 | $30,618 | $785 |
| Vesicare | 60 | $26,110 | $435 |
| Rapaflo | 96 | $24,559 | $256 |
| Tamsulosin | 655 | $18,652 | $28 |
| Enablex | 52 | $18,100 | $348 |
| Jalyn | 80 | $17,513 | $219 |
| Methenamine Hippurate | 117 | $16,768 | $143 |
| Androgel | 23 | $16,647 | $724 |
| Finasteride | 505 | $16,206 | $32 |
| Trospium Chloride | 27 | $5,359 | $198 |
| Nitrofurantoin | 57 | $4,559 | $80 |
| Cialis | 19 | $4,407 | $232 |
| Potassium Citrate | 41 | $4,360 | $106 |
| Estrace | 29 | $4,137 | $143 |
| Nitrofurantoin Mono-Macro | 53 | $3,882 | $73 |
| Oxybutynin Chloride Er | 40 | $3,877 | $97 |
| Bicalutamide | 56 | $3,700 | $66 |
| Trimethoprim | 134 | $2,936 | $22 |
| Terazosin | 108 | $1,525 | $14 |
| Alfuzosin | 28 | $1,260 | $45 |
| Oxybutynin Chloride | 41 | $1,248 | $30 |
| Gabapentin | 16 | $1,123 | $70 |
| Hydroxyzine | 40 | $835 | $21 |
| Sulfamethoxazole-Trimethoprim | 120 | $711 | $6 |
| Levofloxacin | 84 | $591 | $7 |
| Cephalexin | 70 | $492 | $7 |
| Tramadol | 80 | $346 | $4 |
| Ciprofloxacin | 46 | $265 | $6 |
| Doxazosin Mesylate | 13 | $187 | $14 |
| Amoxicillin | 32 | $132 | $4 |
| Amitriptyline | 14 | $112 | $8 |
| Hydrocodone-Acetaminophen | 11 | $86 | $8 |
Money from drug and device companies
$2,705 in 2025
| 2025 | 25 | 84 | None | $2,705 |
| 2024 | 25 | 76 | None | $2,483 |
| 2023 | 22 | 99 | None | $2,977 |
| 2022 | 28 | 123 | $5,588 | $10,283 |
| 2021 | 23 | 81 | $2,144 | $3,754 |
| 2020 | 24 | 78 | $2,545 | $4,358 |
| 2019 | 22 | 99 | None | $2,312 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Janssen Biotech | Erleada | $367 | 9 payments
|
| Dendreon Pharmaceuticals | Provenge | $307 | 5 payments
|
| Abbvie | Botox | $278 | 13 payments
|
| Biotissue Holdings | None | $235 | 2 payments
|
| Bayer Healthcare Pharmaceuticals | Nubeqa | $166 | 4 payments
|
| Pfizer | Xtandi | $157 | 7 payments
|
See all 84 published payments
| Verity Pharmaceuticals | Meals · 2025-12-16 | Trelstar | $22 |
| Astellas Pharma US | Meals · 2025-12-16 | Xtandi | $30 |
| Abbvie | Meals · 2025-12-11 | Botox | $22 |
| Urogen Pharma | Meals · 2025-12-11 | Jelmyto | $22 |
| Janssen Biotech | Meals · 2025-12-09 | Erleada | $35 |
| Abbvie | Meals · 2025-12-09 | Lupron Depot | $12 |
| Sumitomo Pharma America | Meals · 2025-11-21 | Gemtesa | $20 |
| Ferring Pharmaceuticals | Meals · 2025-11-19 | Adstiladrin | $19 |
| Urogen Pharma | Meals · 2025-11-11 | None | $20 |
| Edap Technomed | Meals · 2025-11-11 | Focal One | $61 |
| Abbvie | Meals · 2025-11-03 | Botox | $23 |
| Sumitomo Pharma America | Meals · 2025-10-30 | Orgovyx | $17 |
| Astellas Pharma US | Meals · 2025-10-29 | Xtandi | $24 |
| Progenics Pharmaceuticals | Meals · 2025-10-22 | Pylarify | $20 |
| Dendreon Pharmaceuticals | Meals · 2025-10-14 | Provenge | $23 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-10-09 | Lynparza | $18 |
| Accord Healthcare | Meals · 2025-10-09 | Camcevi | $19 |
| Endo USA | Meals · 2025-10-07 | Xiaflex | $29 |
| Abbvie | Meals · 2025-10-07 | Lupron Depot | $16 |
| Astellas Pharma US | Meals · 2025-09-30 | Xtandi | $23 |
| Janssen Biotech | Meals · 2025-09-25 | Erleada | $34 |
| Sumitomo Pharma America | Meals · 2025-09-19 | Gemtesa | $24 |
| Janssen Biotech | Meals · 2025-09-10 | Rybrevant | $31 |
| Ferring Pharmaceuticals | Meals · 2025-09-10 | Adstiladrin | $14 |
| Pfizer | Meals · 2025-09-05 | Xtandi | $23 |
| Urogen Pharma | Meals · 2025-09-03 | Zusduri | $28 |
| Verity Pharmaceuticals | Meals · 2025-08-28 | Tlando | $27 |
| Abbvie | Meals · 2025-08-27 | Botox | $28 |
| Merck Sharp & Dohme | Meals · 2025-08-27 | Lynparza | $28 |
| Abbvie | Meals · 2025-08-21 | Lupron Depot | $8 |
| Merck Sharp & Dohme | Education · 2025-08-19 | Lynparza | $26 |
| Dendreon Pharmaceuticals | Meals · 2025-08-13 | Provenge | $29 |
| Urogen Pharma | Meals · 2025-08-06 | None | $20 |
| Dendreon Pharmaceuticals | Meals · 2025-07-29 | Provenge | $101 |
| Abbvie | Meals · 2025-07-22 | Botox | $27 |
| Accord Healthcare | Meals · 2025-07-19 | Camcevi | $17 |
| Ferring Pharmaceuticals | Meals · 2025-07-16 | Adstiladrin | $18 |
| Pfizer | Meals · 2025-07-15 | Xtandi | $24 |
| Astellas Pharma US | Meals · 2025-07-10 | Xtandi | $19 |
| Abbvie | Meals · 2025-07-09 | Lupron Depot | $26 |
| Teleflex | Meals · 2025-07-09 | Barrigel | $89 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-07-08 | Nubeqa | $23 |
| Immunitybio | Meals · 2025-07-02 | Anktiva | $17 |
| Progenics Pharmaceuticals | Meals · 2025-07-01 | Pylarify | $27 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-06-14 | Nubeqa | $113 |
| Sagent Pharmaceuticals | Meals · 2025-06-12 | Glydo | $18 |
| Pfizer | Meals · 2025-06-11 | Xtandi | $30 |
| Sumitomo Pharma America | Meals · 2025-06-03 | Gemtesa | $21 |
| Abbvie | Meals · 2025-05-29 | Botox | $26 |
| Accord Healthcare | Meals · 2025-05-23 | Camcevi | $14 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-05-21 | Nubeqa | $22 |
| Bayer Healthcare Pharmaceuticals | Education · 2025-05-21 | Nubeqa | $9 |
| Pfizer | Meals · 2025-05-20 | Xtandi | $24 |
| Antares Pharma | Meals · 2025-05-14 | Xyosted | $16 |
| Abbvie | Meals · 2025-05-13 | Lupron Depot | $15 |
| Janssen Biotech | Meals · 2025-05-12 | Erleada | $36 |
| Ferring Pharmaceuticals | Meals · 2025-05-07 | Adstiladrin | $51 |
| Verity Pharmaceuticals | Meals · 2025-04-16 | Tlando | $33 |
| Coloplast | Meals · 2025-04-15 | Titan | $24 |
| Abbvie | Meals · 2025-04-10 | Lupron Depot | $22 |
| Abbvie | Meals · 2025-04-09 | Botox | $23 |
| Accord Healthcare | Meals · 2025-04-09 | Camcevi | $19 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-04-05 | Lynparza | $24 |
| Janssen Biotech | Meals · 2025-04-01 | Erleada | $37 |
| Progenics Pharmaceuticals | Meals · 2025-04-01 | Pylarify | $29 |
| Sumitomo Pharma America | Meals · 2025-03-27 | Gemtesa | $15 |
| Janssen Biotech | Meals · 2025-03-25 | Erleada | $40 |
| Janssen Biotech | Meals · 2025-03-25 | Rybrevant | $94 |
| Janssen Biotech | Meals · 2025-03-25 | Rybrevant | $29 |
| Sun Pharmaceutical Industries | Meals · 2025-03-19 | Yonsa | $32 |
| Abbvie | Meals · 2025-03-17 | Botox | $30 |
| Ferring Pharmaceuticals | Meals · 2025-03-11 | Adstiladrin | $27 |
| Procept Biorobotics | Meals · 2025-03-11 | Aquabeam Robotic System | $118 |
| Pfizer | Meals · 2025-02-26 | Xtandi | $23 |
| Pfizer | Meals · 2025-02-26 | Xtandi | $3 |
| Janssen Biotech | Meals · 2025-02-25 | Erleada | $32 |
| Dendreon Pharmaceuticals | Meals · 2025-02-22 | Provenge | $135 |
| Myriad Genetic Laboratories | Meals · 2025-02-17 | Myrisk | $21 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-01-28 | Lynparza | $22 |
| Biotissue Holdings | Meals · 2025-01-22 | None | $113 |
| Dendreon Pharmaceuticals | Meals · 2025-01-22 | Provenge | $19 |
| Biotissue Holdings | Meals · 2025-01-20 | None | $122 |
| Sumitomo Pharma America | Meals · 2025-01-17 | Orgovyx | $14 |
| Pfizer | Meals · 2025-01-14 | Xtandi | $29 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $2,483
| Dendreon Pharmaceuticals | Provenge | $701 | 8 payments
|
| Sumitomo Pharma America | Gemtesa | $307 | 15 payments
|
| Abbvie | Lupron Depot | $215 | 11 payments
|
| Bayer Healthcare Pharmaceuticals | Nubeqa | $206 | 6 payments
|
| Axonics | Axonics | $167 | 2 payments
|
| Astellas Pharma US | Xtandi | $109 | 1 payment
|
| Sun Pharmaceutical Industries | Yonsa | $105 | 3 payments
|
| Accord Healthcare | Camcevi | $78 | 4 payments
|
| Merck Sharp & Dohme | Keytruda | $67 | 2 payments
|
| Alnylam Pharmaceuticals | Oxlumo | $57 | 2 payments
|
| Myriad Genetic Laboratories | Prolaris | $57 | 3 payments
|
| Pfizer | Xtandi | $55 | 2 payments
|
| Ferring Pharmaceuticals | Adstiladrin | $52 | 3 payments
|
| Olympus America | Itind System | $46 | 2 payments
|
| Bluewind Medical | Revi | $41 | 2 payments
|
| Novartis Pharmaceuticals | Pluvicto | $32 | 1 payment
|
| Coloplast | Titan | $29 | 1 payment
|
| Verity Pharmaceuticals | Tlando | $26 | 1 payment
|
| Blue Earth Diagnostics | Posluma | $24 | 1 payment
|
| Amgen | Prolia | $24 | 1 payment
|
| Urogen Pharma | Jelmyto | $19 | 1 payment
|
| Janssen Biotech | Erleada | $19 | 1 payment
|
| Endo Pharmaceuticals | Xiaflex | $17 | 1 payment
|
| Conmed | Airseal | $15 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Lynparza | $13 | 1 payment
|
2023: $2,977
| Sumitomo Pharma America | Gemtesa | $442 | 22 payments
|
| AstraZeneca Pharmaceuticals LP | Lynparza | $344 | 7 payments
|
| Boston Scientific | Advance Xp | $323 | 7 payments
|
| Myriad Genetic Laboratories | Myrisk | $268 | 7 payments
|
| Bayer Healthcare Pharmaceuticals | Nubeqa | $227 | 10 payments
|
| UroGen Pharma | None | $204 | 2 payments
|
| Dendreon Pharmaceuticals | Provenge | $181 | 3 payments
|
| PROCEPT BioRobotics | Aquabeam Robotic System | $177 | 2 payments
|
| Janssen Biotech | Erleada | $125 | 6 payments
|
| Pfizer | Xtandi | $117 | 5 payments
|
| Coloplast | Titan | $101 | 2 payments
|
| Astellas Pharma US | Xtandi | $78 | 3 payments
|
| Photocure | Cysview | $73 | 1 payment
|
| Teleflex | Urolift | $66 | 2 payments
|
| Sun Pharmaceutical Industries | Yonsa | $60 | 2 payments
|
| AbbVie | Botox | $50 | 3 payments
|
| Blue Earth Diagnostics | Posluma | $43 | 2 payments
|
| Antares Pharma | Nocdurna | $24 | 1 payment
|
| Supernus Pharmaceuticals | Xyosted | $23 | 1 payment
|
| AngioDynamics | Nanoknife | $21 | 1 payment
|
| Foundation Medicine | Foundationone Liquid Cdx | $17 | 1 payment
|
| Tolmar | Eligard | $13 | 1 payment
|
2022: $10,283
| Bayer HealthCare Pharmaceuticals | Nubeqa | $7,836 | 23 payments
|
| Urovant Sciences | Gemtesa | $422 | 27 payments
|
| Dendreon Pharmaceuticals | Provenge | $276 | 5 payments
|
| Astellas Pharma US | Xtandi | $224 | 14 payments
|
| Boston Scientific | Advance Xp | $179 | 4 payments
|
| Janssen Biotech | Erleada | $179 | 9 payments
|
| UroGen Pharma | Jelmyto | $149 | 3 payments
|
| PROCEPT BioRobotics | Aquabeam Robotic System | $134 | 1 payment
|
| Teleflex | Urolift System | $128 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Lynparza | $77 | 4 payments
|
| Blue Earth Diagnostics | Axumin | $69 | 3 payments
|
| Axonics | Axonics | $62 | 3 payments
|
| TOLMAR Pharmaceuticals | Eligard | $56 | 3 payments
|
| BioTissue Holdings | Neox | $56 | 1 payment
|
| Myriad Genetic Laboratories | Brac Cdx | $54 | 3 payments
|
| Abbvie | Botox | $52 | 3 payments
|
| Amgen | Prolia | $46 | 2 payments
|
| Endo Pharmaceuticals | Xiaflex | $40 | 2 payments
|
| Olympus America | Itind System | $40 | 2 payments
|
| Progenics Pharmaceuticals | Pylarify | $36 | 2 payments
|
| Sun Pharmaceutical Industries | Yonsa | $34 | 1 payment
|
| Ethicon US | Enseal | $30 | 1 payment
|
| Palette Life Sciences | None | $24 | 1 payment
|
| Philips Electronics North America | (4504) Uronav Add on | $22 | 1 payment
|
| Myovant Sciences | Orgovyx | $21 | 1 payment
|
| Verity Pharmaceuticals | Trelstar | $13 | 1 payment
|
| Coloplast | Speedicath | $12 | 1 payment
|
| SRS Medical Systems | Urocuff | $12 | 1 payment
|
2021: $3,754
| Bayer HealthCare Pharmaceuticals | Xofigo | $1,410 | 3 payments
|
| Janssen Biotech | Erleada | $962 | 8 payments
|
| Sanara MedTech | Celleraterx | $156 | 1 payment
|
| Astellas Pharma US | Myrbetriq | $138 | 14 payments
|
| Myriad Genetic Laboratories | Bracanalysis Cdx | $132 | 6 payments
|
| Myovant Sciences | Orgovyx | $130 | 8 payments
|
| TOLMAR Pharmaceuticals | Eligard | $120 | 7 payments
|
| Pfizer | Xtandi | $107 | 5 payments
|
| Amgen | Prolia | $81 | 3 payments
|
| Dendreon Pharmaceuticals | Provenge | $72 | 3 payments
|
| Boston Scientific | Spaceoar Vue | $64 | 3 payments
|
| Allergan | Botox | $51 | 3 payments
|
| Axonics | Axonics R-Snm System | $50 | 1 payment
|
| AbbVie | Lupron Depot | $48 | 3 payments
|
| Blue Earth Diagnostics | Axumin | $43 | 2 payments
|
| Urogen Pharma | Jelmyto | $40 | 2 payments
|
| Merck Sharp & Dohme | Keytruda | $36 | 2 payments
|
| AstraZeneca Pharmaceuticals LP | Lynparza | $35 | 2 payments
|
| Medtronic | Signia | $19 | 1 payment
|
| Coloplast | Speedicath | $17 | 1 payment
|
| Sun Pharmaceutical Industries | Yonsa | $17 | 1 payment
|
| Pacira Pharmaceuticals | Exparel | $16 | 1 payment
|
| Antares Pharma | Xyosted | $12 | 1 payment
|
2020: $4,358
| Bayer HealthCare Pharmaceuticals | Xofigo | $2,716 | 6 payments
|
| Dendreon Pharmaceuticals | Provenge | $237 | 8 payments
|
| TOLMAR Pharmaceuticals | Eligard | $177 | 10 payments
|
| Astellas Pharma US | Xtandi | $171 | 14 payments
|
| Ferring Pharmaceuticals | Firmagon | $167 | 3 payments
|
| Clovis Oncology | Rubraca | $165 | 3 payments
|
| Pfizer | Xtandi | $161 | 5 payments
|
| Janssen Biotech | Erleada | $83 | 4 payments
|
| Allergan | Botox | $70 | 4 payments
|
| Amgen | Xgeva | $60 | 2 payments
|
| Endo Pharmaceuticals | Aveed | $60 | 3 payments
|
| Coloplast | Continence Care | $58 | 2 payments
|
| Agiliti Surgical | None | $38 | 2 payments
|
| Boston Scientific | Advantage Fit | $32 | 1 payment
|
| AbbVie | Lupron Depot | $32 | 2 payments
|
| Merck Sharp & Dohme | Keytruda | $20 | 1 payment
|
| Baudax Bio | Anjeso | $20 | 1 payment
|
| Medtronic USA | Interstim | $16 | 1 payment
|
| Myriad Genetic Laboratories | Bracanalysis Cdx | $14 | 1 payment
|
| Ambu | None | $13 | 1 payment
|
| Sun Pharmaceutical Industries | Yonsa | $13 | 1 payment
|
| Sagent Pharmaceuticals | Glydo | $12 | 1 payment
|
| NeoTract | Urolift | $12 | 1 payment
|
| Foundation Medicine | Foundationone | $12 | 1 payment
|
2019: $2,312
| NeoTract | Urolift | $654 | 9 payments
|
| Dendreon Pharmaceuticals | Provenge | $224 | 9 payments
|
| Ferring Pharmaceuticals | Firmagon | $201 | 6 payments
|
| Astellas Pharma US | Xtandi | $186 | 17 payments
|
| Pfizer | Premarin | $160 | 12 payments
|
| Janssen Biotech | Erleada | $158 | 13 payments
|
| Boston Scientific | Dakota | $148 | 4 payments
|
| Allergan | Botox | $143 | 7 payments
|
| Bayer HealthCare Pharmaceuticals | Xofigo | $70 | 4 payments
|
| AbbVie | Lupron Depot | $62 | 3 payments
|
| Photocure | Cysview | $55 | 1 payment
|
| Medtronic USA | Interstim | $39 | 2 payments
|
| AMAG Pharmaceuticals | Intrarosa | $36 | 2 payments
|
| Endo Pharmaceuticals | Aveed | $30 | 2 payments
|
| TOLMAR Pharmaceuticals | Eligard | $25 | 1 payment
|
| Blue Earth Diagnostics | Axumin | $25 | 1 payment
|
| Richard Wolf Medical Instruments | None | $18 | 1 payment
|
| Sun Pharmaceutical Industries | Yonsa | $18 | 1 payment
|
| Amgen | None | $16 | 1 payment
|
| TherapeuticsMD | Imvexxy | $16 | 1 payment
|
| Retrophin | (815) Thiola | $14 | 1 payment
|
| Metuchen Pharmaceuticals | Stendra | $13 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| PFIZER INC. · Prosper A Multinational Phase 3 Randomized Doubleblind Placebocontrolled Efficacy and Safety Study of Enzalutamide in Patients With Nonmetastatic Castrationresistant Prostate Cancer · 2021 | Their institution | $776 |
| PFIZER INC. · Prosper A Multinational Phase 3 Randomized Doubleblind Placebocontrolled Efficacy and Safety Study of Enzalutamide in Patients With Nonmetastatic Castrationresistant Prostate Cancer · 2020 | Their institution | $719 |
| PFIZER INC. · Prosper A Multinational Phase 3 Randomized Doubleblind Placebocontrolled Efficacy and Safety Study of Enzalutamide in Patients With Nonmetastatic Castrationresistant Prostate Cancer · 2019 | Their institution | $259 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 87.7 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1053403774
- Licence
- CA G64478California G64478: Current · expires 2028-06-30
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Medicaid ID
- CA 00G644780
- Taxonomy
- Urology (208800000X)
- Mailing address
- 225 Prado Rd Ste D, San Luis Obispo, CA, 93401
- NPI first listed
- 2006-09-29
- NPI last updated
- 2022-11-22
- NPI record certified
- 2022-11-22
This is when the NPI record was last certified, not a medical board exam.